GlassScriptPhysician profile
Amanda Amini
NPI 1174939094
$3,117.51
in general payments reported to CMS, 2019-2025
35 companies · $752 in 2025
The $752 reported for 2025 was more than what 78% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $237 · 2022: $845 · 2023: $595 · 2024: $688 · 2025: $752.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,985 · Education: $50.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,984.82 |
| Education | $50.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $431.40 | 2022-2025 | Farxiga, Breztri, Fasenra |
| Glaxosmithkline, LLC. | $344.05 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $305.37 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $252.66 | 2022-2025 | Spravato |
| Lilly USA, LLC | $176.90 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Sanofi-Aventis U.S. LLC | $173.84 | 2021-2025 | |
| Radius Health, INC. | $154.77 | 2023-2025 | Tymlos |
| Antares Pharma, INC. | $146.72 | 2021-2022 | |
| Pfizer INC. | $140.57 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $93.52 | 2023-2024 | Xifaxan, Trulance |
| Novo Nordisk INC | $83.64 | 2024-2025 | Saxenda, Wegovy, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $80.68 | 2024-2025 | Kerendia |
| Astellas Pharma US INC | $60.52 | 2024 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $59.05 | 2021-2024 | Jardiance |
| Ars Pharmaceuticals Operations, INC. | $50.31 | 2025 | Neffy |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Currax Pharmaceuticals LLC | $50.00 | 2023 | Nexletol |
| Amgen INC. | $47.03 | 2022-2025 | Prolia, Evenity, Prolia |
| Seqirus USA INC | $46.07 | 2021-2025 | Flucelvax, Fluad |
| Biohaven Pharmaceutical Holding Company LTD. | $45.15 | 2022 | |
| Novartis Pharmaceuticals Corporation | $41.12 | 2023-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $39.09 | 2021-2022 | |
| Sanofi Pasteur INC. | $38.19 | 2022-2023 | |
| Exact Sciences Corporation | $28.58 | 2025 | Cologuard Collection Kit |
| Teva Pharmaceuticals USA, INC. | $28.41 | 2022 | |
| Acadia Pharmaceuticals INC | $25.47 | 2025 | Daybue |
| Microtransponder, INC. | $24.74 | 2025 | |
| Biohaven Pharmaceuticals, INC. | $23.87 | 2021 | |
| Tactile Systems Technology INC | $21.47 | 2022 | |
| Almatica Pharma LLC | $19.85 | 2025 | Loreev Xr, Teriparatide |
| Hologic Sales and Service, LLC | $17.86 | 2022 | |
| Avion Pharmaceuticals | $15.97 | 2022 | |
| Abbott Laboratories | $15.47 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $12.24 | 2022 | |
| Boston Scientific Corporation | $11.69 | 2022 | |
| Galderma Laboratories, L.P. | $11.24 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Amini listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.